The GLP-1 Hierarchy
Not all GLP-1s are equal. Here's when to use each — and why upgrading compounds beats stacking them.
First-timer. Proven 15–17% body weight loss in clinical trials. Lowest side effect profile of the three. Ideal if you haven't used GLP-1s before or have moderate weight to lose (20–40 lbs). The single GLP-1 receptor mechanism is well-characterized and predictable.
Plateaued on semaglutide, or starting fresh with more to lose. Dual GIP+GLP-1 mechanism produces ~22% body weight loss. The GIP component improves insulin sensitivity in a way semaglutide doesn't — especially relevant if metabolic syndrome or blood sugar dysregulation are part of the picture.
Already done a GLP-1 cycle, or significant weight to lose (50+ lbs). Adds glucagon agonism to GIP+GLP-1, which drives thermogenesis — your body burns more at rest. ~24% body weight loss in trials. The glucagon activation also carries mild heart rate elevation. This is not a starting point — it's a next step.
The right move is upgrading, not stacking. Each compound in this hierarchy activates additional receptor pathways — tirzepatide adds GIP, retatrutide adds glucagon. This is additive mechanism, not additive receptor binding. Stacking compounds at the same receptor level produces diminishing returns and elevated side effect risk without meaningful efficacy gains.
The Healing Stack
Not just BPC + TB-500. Here's the phased approach — local repair first, then systemic amplification, then remodeling.
250–500mcg/day subQ near injury site. BPC-157 drives local angiogenesis and collagen synthesis. This is your foundation — it starts at the injury site and begins building blood supply to damaged tissue. Proximity matters here; injecting near the site concentrates the effect where it's needed.
5mg twice weekly for 2 weeks, then 5mg once weekly. TB-500 works systemically — it travels through the bloodstream and signals tissue repair across multiple sites simultaneously. The overlap with Phase 1 (days 14–28) is intentional: BPC establishes local repair, then TB-500 amplifies systemically while that foundation is in place.
1–2mg/day or 2–3x weekly. GHK-Cu activates roughly 4,000 genes associated with tissue remodeling, collagen synthesis, and anti-inflammatory signaling. It shifts the repair from "acute healing" to "quality tissue reconstruction." This is how you ensure the healed tissue is better, not just closed.
Use Wolverine (BPC+TB-500 pre-blended) when you want simplicity and systemic effect across multiple areas. Run them individually when you want to phase the protocol or target a specific local injury with high-concentration BPC at the site.
A pre-blended skin and cellular repair stack: GHK-Cu activates 4,000+ tissue remodeling and collagen genes, BPC-157 drives vascular repair and mucosal regeneration, and TB-500 provides the anti-fibrotic structural support that ensures clean tissue rather than scar formation. Administered subcutaneously. Use when the goal shifts from acute injury repair toward ongoing skin quality and cellular regeneration.
The arginate form is not necessarily inferior, but the evidence base is thinner. If COA quality and research alignment matter to you, confirm which salt your vendor carries. For oral/topical use the distinction matters less. For injectable protocols, choose acetate.
The Longevity Stack
Hitting aging at the cellular level — telomere extension, NAD+ repletion, and mitochondrial signaling.
10mg/day for 10–20 days. Then stop. Epithalon activates telomerase — the enzyme that lengthens telomeres. Telomere lengthening is associated with slower biological aging and improved cellular repair capacity. Running a pulse course, not chronic dosing.
500mg injected 1–3x weekly, ongoing. NAD+ is the master fuel molecule for cellular energy and DNA repair. Injectable form bypasses the NAMPT conversion bottleneck that makes oral NMN and NR unreliable in older individuals.
5mg 2–3x weekly, on workout days. Mitochondria-derived peptide that activates AMPK — the cellular energy sensor. AMPK activation synergizes with exercise-induced metabolic signaling. 8–12 week cycles with 4 weeks off.
1–2mg/day. Activates 4,000+ repair and regeneration genes. Research shows reversal of gene expression patterns in aging tissue toward younger profiles. Pairs well with the core longevity stack as an ongoing remodeling signal.
The body's primary intracellular antioxidant. Injectable glutathione bypasses first-pass liver degradation, delivering serum levels that oral supplements cannot match. Neutralizes reactive oxygen species, regenerates vitamins C and E, and supports phase II liver detoxification. Cellular oxidative load is one of the primary drivers of biological aging — glutathione addresses it directly. 500–1500mg subcutaneous, 2–3x weekly.
Methylcobalamin is the bioactive form of B12 — directly usable without hepatic conversion, unlike cyanocobalamin. Injectable B12 addresses fatigue, neurological function, and methylation support at doses impossible to achieve orally. Works synergistically with injectable NAD+ — both feed the mitochondrial energy and DNA repair pathways. 1–5mg subcutaneous, 1–3x weekly.
Standard approach: 10–20 day course, then 4–6 months off before the next course. Most practitioners run 1–2 courses per year. This mirrors how the body's own telomere maintenance signals work — pulsatile, not continuous.
Injectable NAD+ bypasses that bottleneck entirely. You're loading the molecule that matters directly into circulation. For people over 40 — where NAMPT decline is most significant — this distinction is material. Oral precursors work better in younger individuals whose NAMPT activity is still robust.
Semax + Selank — The Focus/Calm Pairing
Semax sharpens and amplifies. Selank removes the noise. Together you get heightened cognitive function without the wired-but-distracted feeling that pure stimulants produce.
Dramatically raises BDNF and NGF in the brain. BDNF is essentially fertilizer for neurons — it drives neuroplasticity, memory encoding, and cognitive resilience. Nasal administration reaches the brain rapidly via the olfactory pathway. SubQ also works but nasal is faster onset for cognitive effects.
Stabilizes enkephalins and modulates GABA-A receptors — produces anxiolytic effect without sedation or dependency. This is not a benzodiazepine mechanism. No tolerance development at standard doses. The result is reduced cognitive interference from anxiety without blunting the signal Semax creates.
Intranasal: 1–2 drops per nostril (Semax), 1–2 drops (Selank), 2–3x daily. Faster onset, preferred for acute cognitive enhancement.
SubQ: 100–300mcg each, 1–2x daily. Slower onset, more sustained effect. Some prefer this for consistent all-day focus rather than acute peaks.
Standard cycle: 3–4 weeks on, 1–2 weeks off. During the off period, receptor sensitivity resets. This preserves the sharpness of effect on the next cycle and prevents the kind of gradual drift where you're taking the compound but no longer feeling it.
CJC + Ipamorelin — What Most People Get Wrong
There are two completely different compounds both sold as "CJC-1295." Knowing the difference changes your protocol entirely.
Also called Mod GRF 1-29. Half-life: ~30 minutes. Mimics a natural GH pulse — it rises and clears. Preferred by experienced practitioners for this reason. The body's own GH release is pulsatile; a short-acting analogue preserves that pattern and maintains pituitary sensitivity over time.
Half-life: 6–8 days. Keeps GH elevated continuously. This disrupts natural GH pulsatility and may desensitize the pituitary over longer cycles. Requires longer off-cycle breaks to restore sensitivity. Not a superior compound — a different tool with different tradeoffs.
The cleanest GHRP available. Other GHRPs (GHRP-2, GHRP-6) spike cortisol and prolactin alongside GH. Ipamorelin produces a clean GH pulse with minimal cortisol or prolactin activation. This is why it's preferred for longer-term use and why it stacks well with CJC without compounding the hormonal side effect profile.
Kisspeptin stimulates GnRH release, which drives LH and FSH, which drive testosterone production. It's used in post-cycle support and in cases of secondary hypogonadism where the testes are functional but the hypothalamic signal is weak. This is a different mechanism than testosterone replacement — it works through the body's own pathway rather than bypassing it.
The KLOW Stack
Why four compounds beat one — gut inflammation, permeability, and structural damage involve multiple simultaneous failures. Each compound addresses a different phase.
Inhibits NF-κB — the master switch of gut inflammation. Reduces the cytokine storm that perpetuates gut damage. This is the "stop the bleeding" phase. Nothing else in the stack is effective if the inflammatory environment isn't controlled first.
After inflammation is controlled, the architecture of the gut lining needs to be rebuilt. GHK-Cu activates tissue remodeling genes and drives collagen synthesis in the intestinal wall. This is structural repair — not just symptom management.
Epithelial cells need to migrate into damaged areas to close gaps in the gut lining. TB4 fragment provides the cell migration signal. Without this, the remodeling phase produces disorganized repair rather than organized epithelial coverage.
Mucosal lining repair and angiogenesis. Brings blood supply to damaged areas and accelerates collagen synthesis in the intestinal wall. BPC-157 is particularly well-studied in gut contexts — the majority of early BPC research was on GI applications.
IBS that hasn't responded to elimination diets. Post-antibiotic gut disruption (antibiotics damage the epithelium directly, not just the flora). Leaky gut. Chronic bloating and inconsistent digestion despite clean eating. If you've tried the dietary approach and it's not working, the issue is likely structural — this stack addresses the architecture.
The LH Pulse Stack
BPC-157, Kisspeptin-10, and PT-141 — restoring hypothalamic-pituitary-ovarian signaling from the top down, not the bottom up.
250–500mcg daily. Acts as the systemic repair signal — reduces gut-brain axis inflammation, stabilizes the ANS, and creates the low-inflammation environment in which hormonal signaling can normalize. BPC-157 has documented effects on nitric oxide pathways and GABA modulation, both of which are relevant to neuroendocrine signaling.
Kisspeptin is the master gatekeeper of GnRH release. Without Kisspeptin signaling, the hypothalamus cannot initiate the LH/FSH pulse that drives ovulation. In PCOS and post-OCP suppression, Kisspeptin signaling is often blunted. This compound directly activates the GnRH pulse generator — restoring the upstream signal rather than supplementing downstream hormones. Dosing: 100–200mcg 2–3x weekly, subcutaneous.
Acts on melanocortin receptors (MC3R and MC4R) in the CNS — not on sex hormone receptors directly. PT-141 produces arousal and libido restoration through central nervous system pathways, making it effective even in cases where hormonal levels are technically normal but the CNS response is blunted. 0.5–2mg subcutaneous, 1–2 hours before desired effect. Not for daily use — 2–3x weekly max.
Healthy female hormonal cycling depends on pulsatile LH release — roughly one pulse per 60–90 minutes in the follicular phase. Kisspeptin-10 directly drives this pulsatility by activating the hypothalamic GnRH pulse generator. When this pulse is weak or absent (common after OCP use, in PCOS, or under chronic stress), downstream estrogen and progesterone patterns become erratic regardless of what those hormones read on a blood panel. Fix the signal, not just the numbers.
Run this stack for 8–12 weeks minimum before assessing response. Hormonal systems have long feedback loops. BPC-157 can be used continuously. Kisspeptin-10 should be cycled (8 weeks on, 4 weeks off) to prevent receptor downregulation. PT-141 is used on an as-needed basis, not continuously.
The Delta Sleep Stack
Epitalon, DSIP, and CJC-1295 no-DAC — engineering deep sleep stages and synchronizing growth hormone release with the body's natural nocturnal pulse.
In addition to its telomerase-activating function, Epitalon has documented effects on melatonin regulation and circadian rhythm normalization. It restores the proper amplitude of the melatonin secretion curve — particularly in older individuals where melatonin production flattens. 10mg before sleep during pulse course (10–20 days).
DSIP was first identified in the thalamus of sleeping rabbits. It selectively promotes slow-wave sleep (SWS) — specifically stage N3, which is where the majority of physical restoration and immune maintenance occurs. Unlike sleep pharmaceuticals, DSIP doesn't suppress REM or produce next-day cognitive impairment. Dosing: 200–400mcg subcutaneous, 30–60 minutes before bed. Use 3–5x weekly.
Growth hormone's largest natural release occurs in the first 90 minutes of sleep. CJC-1295 without DAC amplifies this nocturnal pulse without disrupting pulsatility — it creates a physiological GH surge timed to the body's natural window. This is why timing matters: inject 15–30 minutes before sleep for maximum pulse amplification. 100mcg pre-sleep, 3–5x weekly.
Stage N3 (slow-wave/delta sleep) is not just rest — it's when human growth hormone reaches its 24-hour peak, when cortisol hits its nadir, and when the glymphatic system clears metabolic waste from the brain. Poor SWS directly impairs protein synthesis, memory consolidation, and immune function. DSIP specifically targets this stage, while Epitalon and CJC work together to maximize what happens within that window.
The Fat Oxidation Stack
AOD-9604, MOTS-c, and micro-dose Semaglutide — hitting adipose-specific lipolysis, mitochondrial efficiency, and appetite regulation without receptor saturation or IGF-1 elevation.
AOD-9604 is a fragment of growth hormone (amino acids 176–191) that retains HGH's fat-burning activity without stimulating IGF-1 production. This is the critical distinction: standard HGH therapy elevates IGF-1, which drives both anabolism and potential proliferative risks. AOD-9604 activates the beta-3 adrenergic receptor in adipose tissue, directly stimulating lipolysis — and it does this only in fat cells, not uniformly across tissues. 250–500mcg daily, subcutaneous.
A mitochondria-derived peptide that activates AMPK — the cellular energy sensor that regulates how cells decide whether to burn fat or store it. MOTS-c promotes fatty acid oxidation and increases the rate at which mitochondria process fats for fuel. It also improves insulin sensitivity in muscle tissue, directing glucose away from fat storage. 5mg 2–3x weekly on training days for maximum AMPK synergy with exercise.
At micro-doses (0.1–0.25mg weekly), Semaglutide provides appetite modulation without the full GLP-1 saturation effect or the nausea/GI side effects associated with standard doses. The goal here is not aggressive appetite suppression — it's reducing the appetite reward signal enough to prevent the caloric overshoot that undermines the fat oxidation the other two compounds drive. Receptor saturation is avoided at these doses.
Standard weight loss approaches (caloric deficit, GLP-1s) reduce fat across the body via systemic caloric mechanisms. AOD-9604 targets adipose tissue specifically through beta-3 adrenergic receptor activation — meaning it can drive lipolysis in fat tissue even in a caloric maintenance state. Combining this with MOTS-c's mitochondrial efficiency gains means the freed fatty acids are actually burned, not reesterified.
The BDNF Stack
Semax, a Dihexa-analogy approach, and systemic BPC-157 — upregulating BDNF, potentiating HGF/MET signaling, and creating the neuroinflammatory environment where new neural connections can actually form and persist.
Semax dramatically upregulates BDNF (Brain-Derived Neurotrophic Factor) and NGF (Nerve Growth Factor) in the prefrontal cortex and hippocampus — the two brain regions most associated with executive function and memory consolidation. BDNF is essentially fertilizer for synaptic connections; without adequate BDNF, new learning cannot be physically encoded in neural architecture. Semax also reduces neuroinflammation, which is the primary obstacle to BDNF's effect in many adults. 100–300mcg intranasal, 2–3x daily.
Dihexa is an HGF (Hepatocyte Growth Factor) potentiator — it amplifies the HGF/MET signaling pathway, which drives synaptogenesis (the formation of new synaptic connections). Research has shown it to be 10 million times more potent than BDNF at driving synaptogenesis in animal models. While access is limited, the mechanism highlights what's possible: directly potentiating the cellular machinery that builds new neural connections rather than just increasing neurotrophic factor expression. Seek properly sourced research-grade material; topical application 1–2mg daily.
BPC-157 has documented neuroprotective effects beyond its well-known gut and joint applications. It upregulates VEGF (vascular endothelial growth factor) in neural tissue, improving cerebral blood flow and oxygenation. It also has documented effects on dopamine and serotonin systems, and reduces neuroinflammatory cytokines that would otherwise blunt BDNF activity. Administered systemically (subcutaneous) rather than near a specific injury site: 250–500mcg daily.
Hippocampal neurogenesis — the growth of new neurons in the hippocampus — continues throughout adult life and is BDNF-dependent. Chronic stress, neuroinflammation, alcohol, and poor sleep all suppress hippocampal BDNF and blunt neurogenesis. This stack addresses all three axes simultaneously: Semax raises BDNF expression, BPC-157 reduces neuroinflammation that inhibits BDNF signaling, and Dihexa potentiates the downstream synaptogenesis that BDNF initiates. The result is not just more neurotrophic factor — it's a complete environment for structural neuroplasticity.
The Anti-Inflammatory Triad
BPC-157, TB-500, and LL-37 — addressing the COX inflammatory cascade, balancing angiogenesis against fibrosis, and deploying antimicrobial-immune dual function.
BPC-157 modulates the COX (cyclooxygenase) pathway — the same pathway targeted by NSAIDs like ibuprofen — but without the gastrointestinal and cardiovascular side effects of chronic NSAID use. It also drives angiogenesis (new blood vessel formation) at injury sites, which is pro-healing, but unlike some compounds it maintains the balance between angiogenesis and fibrosis. Too much angiogenesis without anti-fibrotic signaling produces scar tissue rather than functional tissue. BPC-157 navigates this balance. 250–500mcg daily, subcutaneous or near site.
TB-500's anti-inflammatory and anti-fibrotic properties complement BPC-157's angiogenic effects. TB-500 specifically inhibits myofibroblast differentiation — the cellular process that turns inflammation into scar tissue. Where BPC-157 drives blood supply and collagen synthesis, TB-500 ensures the repair process doesn't overshoot into fibrosis. Together they hit the two failure modes of inflammatory resolution: inadequate repair and excessive scarring. 5mg twice weekly initial load, then 5mg weekly.
LL-37 is a cathelicidin antimicrobial peptide — the only member of its class in humans. It has dual function: antimicrobial (disrupting bacterial and viral membranes) and immunomodulatory (modulating TLR4 signaling and polarizing macrophages toward M2/anti-inflammatory phenotype). This is particularly relevant when inflammation has a persistent infectious driver. LL-37 also drives wound healing through re-epithelialization and has emerging research on biofilm disruption. 1–2mg subcutaneous, 3x weekly.
BPC-157 drives the angiogenic side; TB-500 provides the anti-fibrotic brake. Running them together maintains the physiological balance that produces clean, organized tissue repair. Running BPC-157 alone in a high-fibrosis environment (post-surgery, chronic inflammation) may amplify both beneficial repair and scarring.
The Cardiac Protection Stack
TB-500, BPC-157, and low-dose Hexarelin — protecting cardiac myocytes, driving vascular remodeling, and stimulating the GH receptor in cardiac tissue specifically.
TB-500 has the strongest evidence base for cardiac myocyte protection among available peptides. It activates the Akt/PI3K survival pathway in cardiomyocytes — the same pathway that natural cardioprotection signals use. In ischemia-reperfusion injury models, TB-500 reduces infarct size by approximately 30–40%. It also drives vasculogenesis (new blood vessel formation) in cardiac tissue, which improves perfusion. This isn't performance enhancement — it's the same mechanism the heart uses to protect itself under stress. 5mg twice weekly.
BPC-157 modulates nitric oxide (NO) synthesis and vascular endothelial function. Endothelial dysfunction — the failure of blood vessels to dilate and contract properly — is the earliest detectable sign of cardiovascular pathology, preceding atherosclerosis by years. BPC-157's NO pathway effects directly address endothelial function. It also protects the coronary vasculature from inflammatory damage. 250–500mcg daily, subcutaneous.
Hexarelin is a GHRP with documented cardiac-specific effects that are partially independent of GH release. Cardiac tissue expresses GHS-R (growth hormone secretagogue receptors) that Hexarelin activates directly. This drives anti-apoptotic signaling in cardiomyocytes and improves cardiac output. At low doses (50–100mcg, 3x weekly), Hexarelin's cardiac-specific effects are prominent while minimizing the cortisol and prolactin side effects associated with higher doses or continuous use. Not for daily use at this indication.
This is a protective, not treatment, protocol. If you have active cardiac conditions, this requires medical supervision. For preventive and conditioning use: 8–12 week cycles, with baseline and follow-up cardiovascular markers. TB-500 and BPC-157 can overlap; Hexarelin should be cycled (8 weeks on, 4 weeks off) to prevent GHS-R desensitization.
The Thymic Peptide Stack
Thymosin Alpha-1, LL-37, and BPC-157 — rebuilding thymic immune surveillance, restoring innate antimicrobial defense, and creating the low-inflammation environment where adaptive immunity functions optimally.
Tα1 is a 28-amino acid peptide naturally produced by the thymus — the organ responsible for T-cell maturation. As the thymus atrophies with age (starting as early as the 20s), Tα1 production declines and T-cell quality degrades. Tα1 drives T-cell maturation, upregulates MHC class I and II expression, and activates dendritic cells and NK cells. It has been approved in several countries for use in hepatitis, HIV, and as a cancer immune adjuvant. It also drives IL-2 production, which amplifies the entire adaptive immune cascade. Dosing: 1.6mg subcutaneous 2–3x weekly.
Where Tα1 works on adaptive immunity (T-cells, B-cells), LL-37 strengthens innate immunity — the first-line defense. It's expressed in neutrophils, macrophages, and epithelial cells, and provides immediate antimicrobial response to pathogens before the adaptive system engages. LL-37 also bridges the two immune systems: it activates dendritic cells via TLR4 signaling, converting innate pathogen detection into adaptive immune priming. 1–2mg subcutaneous, 3x weekly.
Chronic inflammation suppresses immune function through elevated cortisol and cytokine-mediated immune cell exhaustion. BPC-157 creates the low-inflammation environment in which both Tα1 and LL-37 can function optimally. Additionally, BPC-157 has documented effects on gut mucosal immunity — since approximately 70% of the immune system resides in gut-associated lymphoid tissue (GALT), gut lining integrity is foundational to immune competence. 250mcg daily, subcutaneous or oral on empty stomach for gut-immune applications.
The thymus is where naive T-cells become functional — either helper T-cells (CD4+) that coordinate immune response, or cytotoxic T-cells (CD8+) that kill infected or cancerous cells. By age 40, the thymus has involuted substantially; by 60, T-cell output is a fraction of its youthful level. This is the primary driver of immunosenescence — not the failure to produce immune cells, but the failure to mature them properly. Tα1 partially restores this maturation signal, improving both the quality and functional diversity of the T-cell repertoire.
The Lean Stack
Ipamorelin, CJC-1295 no-DAC, and AOD-9604 — amplifying pulsatile GH release, preserving pituitary sensitivity, and targeting fat oxidation without elevating IGF-1 or disrupting cortisol.
The cleanest GHRP available. Ipamorelin produces a selective, clean GH pulse — no cortisol elevation, no prolactin spike, no hunger stimulation (unlike GHRP-6). For body recomp, this matters: cortisol is catabolic to muscle and promotes fat storage. A GH-releasing compound that also elevates cortisol partially undermines the recomp goal. Ipamorelin avoids this entirely. 100–200mcg subcutaneous, pre-sleep and/or pre-workout, 3–5x weekly.
CJC-1295 without DAC (Mod GRF 1-29) amplifies the GH pulse that Ipamorelin initiates. Its 30-minute half-life ensures this amplification is pulsatile — it rises and clears in alignment with the natural GH secretion pattern, preserving pituitary sensitivity over the full cycle. This is contrasted with CJC-1295 with DAC, which maintains elevated GH levels continuously and desensitizes the pituitary over time. For long-cycle recomp protocols, preserving pituitary sensitivity is essential. 100mcg alongside each Ipamorelin injection.
AOD-9604 is the GH fragment (176–191) that carries the fat metabolism activity of growth hormone without the IGF-1 elevation. Full HGH therapy drives significant IGF-1 increases — associated with lean mass gains but also with proliferative risks and fluid retention. AOD-9604 delivers the adipose-specific, beta-3 adrenergic receptor-mediated fat oxidation of GH without these systemic effects. This allows fat mobilization to be driven independently of IGF-1 elevation, making it the ideal complement to Ipamorelin/CJC for recomp goals. 250–500mcg daily.
Classic body recomp is difficult because the conditions that favor muscle gain (caloric surplus, high insulin) oppose fat loss, and vice versa. This stack breaks that constraint: Ipamorelin + CJC amplify GH, which is anabolic to muscle through IGF-1-dependent and independent pathways. AOD-9604 drives fat oxidation specifically in adipose tissue through a GH-fragment mechanism that doesn't elevate IGF-1. The result: anabolic signaling in muscle, lipolytic signaling in fat, without the IGF-1 spike that would require cycling to manage.
AOD-9604 can be run continuously — it doesn't act through the pituitary and has no receptor downregulation concern at the adipose beta-3 receptor level at standard doses. This means even during the off cycle for Ipamorelin/CJC, AOD-9604 can continue to drive fat oxidation.
Pens & Auto-Injectors
Pre-loaded pen-format delivery for the most commonly used compounds — no reconstitution, no vials, ready to use out of the box.
Dual GLP-1 + GIP receptor agonist in pen format. Same compound as vial-form Tirzepatide — the pen delivers pre-measured doses without reconstitution. 40mg total per pen. Used for fat loss, appetite regulation, and insulin sensitivity. See the GLP-1 Hierarchy section above for protocol guidance.
GLP-1 + GIP + Glucagon triple agonist in pen format. Most potent fat loss compound available — the glucagon component adds thermogenesis on top of tirzepatide's dual mechanism. 40mg total per pen. For experienced GLP-1 users or those with significant weight to lose (50+ lbs).
BPC-157 + TB-500 pre-blended in pen format. The most popular recovery combination — local tissue repair and systemic healing signal in a single pen. 40mg total. Eliminates the need to reconstitute and combine two separate vials for the standard healing stack.
The Glow Blend (10/10/50mg — GHK-Cu + BPC-157 + TB-500) in pen format. Designed for skin quality, collagen stimulation, and cellular regeneration. 80mg total. Makes the Glow Blend practical as a regular part of a skin and longevity protocol without managing three separate vials.
The KLOW gut stack in pen format. Combines the four-compound gut healing protocol — KPV (NF-κB anti-inflammatory), GHK-Cu (architecture rebuild), BPC-157 (mucosal repair), and TB-500 (anti-fibrotic structural support). 80mg total. Simplifies the multi-compound gut protocol into a single pen.
Injectable NAD+ and methylcobalamin B12 combined in pen format. 1000mg total. Both compounds feed the same mitochondrial energy and DNA repair pathways — pairing them in a single pen makes the longevity maintenance protocol simpler and consistent. Ideal for ongoing use alongside Epithalon pulse courses.
Injectable glutathione in pen format. 1000mg total. Master antioxidant support — cellular oxidative defense, liver phase II detoxification, and vitamin C/E regeneration. The pen format makes consistent glutathione maintenance practical for longevity and detox protocols.
Injectable B-vitamin complex in pen format. 1000mg total. Covers the full B-vitamin spectrum for energy metabolism, methylation support, and neurological function. Injectable delivery bypasses GI absorption variables — meaningful for anyone with gut issues or absorption concerns.
Injectable biotin (vitamin B7) in pen format. 40mg total. Biotin is essential for fatty acid synthesis, amino acid metabolism, and keratin structure — the reason it's associated with hair and nail quality. Injectable form provides reliable absorption compared to oral supplementation, where gut transit and absorption variability reduce effective delivery.
What You Need to Know
The fundamentals behind peptide protocols — so you understand what you're doing, not just what to inject.
The cycle length varies by compound. GLP-1s don't require cycling for efficacy — they're designed for chronic use and the receptor kinetics support that. Peptides that work through pulsatile release (GH peptides, cognitive peptides) need cycling because the natural physiology they're mimicking is itself pulsatile. Mimicking a pulse continuously defeats the mechanism.
Rule: For any vial you'll draw from multiple times, use bacteriostatic water. Sterile water is acceptable only for single-injection reconstitution where you'll use the entire vial in one dose.
For peptides where slow steady absorption is desirable (most recovery, longevity, and metabolic peptides), SubQ is correct. For applications where speed of onset matters — cognitive peptides taken acutely, or BPC-157 for a specific acute injury — SubQ near the site or intranasal routes are preferred depending on the compound.
Understanding this prevents both underdosing (too infrequent relative to half-life) and unnecessary overdosing (injecting daily when the half-life already maintains adequate levels from twice-weekly dosing). When in doubt: shorter half-life = more frequent injections; longer half-life = less frequent.
Red flags: No mass confirmation (purity percentage without MS verification means you know it's pure, not what it's pure of). Purity below 97%. Vague lab names without identifiable accreditation. Lot number mismatch between COA and vial.
Reputable vendors include the lot number on both the COA and the vial. Match them before drawing. If the numbers don't match, the COA is not for the compound you're holding.